July 1, 2022
Sanofi said on June 30 that it has filed its IL-4/IL-13 inhibitor Dupixent (dupilumab) for the additional indication of prurigo nodularis in Japan. Patients with prurigo nodularis suffer from intense, persistent itching characterized by thick skin lesions (nodules). It is...read more